AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Nasopharyngeal Cancer - Global Pipeline Review (H1 2019) by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

May 28, 2019

DUBLIN--(BUSINESS WIRE)--May 28, 2019--

The “Nasopharyngeal Cancer - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Nasopharyngeal Cancer - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 22, 10, 3, 10, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 3, 7 and 1 molecules, respectively.

Scope

Reasons to Buy

Key Topics Covered

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/liecpf

View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005337/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/28/2019 06:38 AM/DISC: 05/28/2019 06:38 AM

http://www.businesswire.com/news/home/20190528005337/en